Alan Tyndall was appointed professor and head of the Department of Rheumatology at the University of Basel in 1991. His main interests are stem cell therapy of autoimmune diseases and systemic sclerosis (scleroderma). He has participated in the working party of the European Science Foundation–sponsored study of investigator-initiated trials and the European Medicines Agency study group regarding third country clinical trials.
Alan has served on the boards of the European Society for Blood and Marrow Transplantation and the European League Against Rheumatism (EULAR) and was a founding member and secretary of the EULAR Scleroderma Trials and Research (EUSTAR) group as well as the World Scleroderma Foundation (based in Basel). He is chairman of the safety committees of 2 NIH-sponsored stem cell trials, is an emeritus professor at the University of Basel, and a board member and co-founder of the bioinformatics company Iterata AG. Alan has published over 230 peer-reviewed papers, 100 of which relate to stem cell therapy, and 30 book chapters.
Alan received his undergraduate medical degree at the University of Sydney in 1972. His postgraduate qualifications are FRACP and FRCP(Ed), with postgraduate experience in Canberra, Sydney, and London.